Figure 7.

Administration of BiZn delayed SKNLP tumor cells lung and liver metastases. A total of 0.2 × 10⁶ SKNLP cells were injected into the adrenal gland, and lung and liver metastases were noted. After 4-week injection of SKNLP cells, mice were treated weekly with i.p. doses of 7.5 mg/kg cisplatin for 3 weeks in cisplatin and cisplatin plus BiZn groups. For the control and BiZn-treated groups (negative control), mice were only treated for 2 weeks because of the large and rapidly progressing tumor size. Luminescence images of lungs and livers were noted. For liver groups, cisplatin- and cisplatin plus BiZn–treated livers had significantly lower total flux when compared to the control group (cisplatin-treated and BiZn combined with cisplatin–treated vs. control group, **P < .01). BiZn-treated livers had significantly lower total flux when compared to the control group (BiZn-treated vs. control group, **P < .01). Cisplatin- and cisplatin plus BiZn–treated livers had no significant difference in total flux. For lung groups, cisplatin- and cisplatin plus BiZn–treated groups had significantly lower total flux when compared to the control group (cisplatin-treated and BiZn combined with cisplatin–treated vs. control group, *P < .05). Cisplatin- and cisplatin plus BiZn–treated tumors had no significant difference in total flux.